In this scenario, the utility of KMT is being demonstrated to enhance the anti-tumor effects of radiotherapy, chemotherapy, and targeted approaches (e.g., VEGF and immune checkpoint inhibitors) across different cancer models, via reductions in tumor nutrient utilization, hypoxia, inflammation, invasion, and angiogenesis, as well as regulation of pathways mediating tumor growth such as mTOR, insulin-PI3K, AMPK-PGC-1α, autophagy, epigenetic signaling, immune recognition, and multiple other pleiotropic mechanisms [68, 126, 158, 166–171]. The gene discussed is INS; the disease is neoplasm.